ArticleActa ophthalmologica2025
Clinical characteristics and treatment outcomes of bilateral myopic macular neovascularization in high myopic patients.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- Defining the critical axial length threshold for transition from physiological growth to pathological fundus structural remodeling in adolescent myopia.Frontiers in cell and developmental biology · 2026Article
- Clinical characteristics and treatment outcomes of bilateral myopic macular neovascularization in high myopic patients.Acta ophthalmologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the clinical features and treatment outcomes of bilateral myopic macular neovascularization (mMNV).
methodsThis single-centre retrospective study included patients with bilateral high myopia who were newly diagnosed with unilateral mMNV (first eye) between January 2008 and July 2020. Patients who presented with mMNV or macular atrophy suggestive of previous mMNV in the fellow eye (second eye) were excluded. Patients were classified into unilateral or bilateral groups based on mMNV development in the second eye during follow-up of >36 months.
resultsNinety-three patients were included with the mean age of 55.4 ± 13.1 years and 71 (76.3%) were female. The mean baseline spherical equivalent was -13.0 ± 5.5 diopters. Of total, 21 (22.6%) developed mMNV in the second eye during the mean follow-up period of 95.1 ± 38.9 months; the cumulative probabilities were 16.2% at 5 years and 28.9% at 10 years after the first eye mMNV development. The uninvolved second eyes of the unilateral group had shorter axial length (AL) and greater subfoveal choroidal thickness than the eyes with mMNV. The unilateral group showed a greater interocular difference in AL than the bilateral group (p < 0.001). The presence of lacquer cracks in the second eye was identified as a significant risk factor for the second eye mMNV development (HR = 5.64, 95% CI: 1.59-20.08, p = 0.008). In the bilateral group, the second eye showed less vision improvement after anti-VEGF treatment, but the final visual acuity and cumulative probability of fovea-involving mMNV-related chorioretinal atrophy did not differ between the eyes.
conclusionsApproximately 30% of bilateral high myopic patients with unilateral mMNV are estimated to develop mMNV in the second eye over a period of 10 years. The presence of lacquer cracks in the second eye was a significant risk factor. The first and second eyes showed comparable treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.